ev3 Inc. Announces Promotion of Pascal E.R. Girin to Lead Global Neurovascular Business and International
PLYMOUTH, Minn., July 21 /EMWNews/ -- ev3 Inc. (Nasdaq: EVVV) today announced that effective July 18, 2008, Pascal E.R. Girin was promoted to Executive Vice President of ev3 Inc. and President, Worldwide Neurovascular and International. In this newly created position, Mr. Girin will lead ev3's worldwide neurovascular business in addition to his current responsibilities as President of International. The company also announced that Matthew Jenusaitis has resigned his position as Senior Vice President of ev3 Inc. and President, Neurovascular Division. Robert Palmisano, President and Chief Executive Officer of ev3 Inc., commented, "I'm delighted to announce Pascal's appointment to this new position to lead our new global neurovascular organization and international operations. Pascal's contributions as our President of International have been exceptional, and his assumption of this role is a natural consequence of the outstanding operational leadership that he has provided since joining ev3. Pascal is a respected member of our operating team and has been a major contributor to the company's growth and success, including the expansion of our worldwide neurovascular business to the #2 overall revenue share position. I look forward to his continued future contributions to ev3 in his new role." Girin joined ev3 in September 2003 as European General Manager. In July 2005, he was promoted to President of International and to Senior Vice President of ev3 Inc. and President of International in August 2007. During his tenure in these positions, ev3's international business expanded to over 60 countries through a direct sales organization and distribution network, and international net sales increased from $30.0 million in 2003 to $107.0 million in 2007. Prior to joining ev3, Mr. Girin served in various capacities at Baxter Healthcare Corporation's BioScience Division in Europe, including Vice President. Mr. Girin received an engineering education at the French Ecole des Mines.
About ev3 Inc. Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of lower extremity vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today -- peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at http://www.ev3.net. ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89